Myriad to Buy Back $200M in Shares
August 16, 2011
Myriad to Buy Back $200M in Shares
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Myriad Highlights RBM Pharma Work, Reports $2M in Q4 Revenues from Companion Diagnostics
August 12, 2011 / ProteoMonitor - Patent Bill Could Make Some Gene Tests Safe from Infringement Suits
June 16, 2011 / GenomeWeb Daily News - Protein Biomarkers for Alzheimer's Predicted to Represent Cumulative $9B Market Over Next Decade
June 3, 2011 / ProteoMonitor - RBM Achieves Milestone in Companion Diagnostic Project with Roche
May 27, 2011 / ProteoMonitor - Myriad to Enter Proteomics Market with $80M Purchase of Rules-Based Medicine
April 29, 2011 / ProteoMonitor